

Glucose-6-Phosphate Dehydrogenase Status and Risk of Hemolysis in *Plasmodium falciparum*-Infected African Children Receiving Single-Dose Primaquine

Alice C. Eziefula,^a Helmi Pett,^b Lynn Grignard,^a Salome Opus,^c Moses Kiggundu,^c Moses R. Kanya,^{c,d} Shunmay Yeung,^a Sarah G. Staedke,^a Teun Bousema,^{a,b} Chris Drakeley^a

Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom^a; Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands^b; Infectious Diseases Research Collaboration, Kampala, Uganda^c; Department of Medicine, Makerere University College of Health Sciences, Kampala, Uganda^d

Glucose-6-phosphate dehydrogenase (G6PD) enzyme function and genotype were determined in Ugandan children with uncomplicated falciparum malaria enrolled in a primaquine trial after exclusion of severe G6PD deficiency by fluorescent spot test. G6PD A– heterozygotes and hemizygotes/homozygotes experienced dose-dependent lower hemoglobin concentrations after treatment. No severe anemia was observed.

Declines in malaria due to *Plasmodium falciparum* have been documented in a number of settings where malaria is endemic. It is debated whether scaling-up of conventional malaria control will sustain these declines or achieve elimination unless augmented by tools that specifically reduce transmission. Primaquine is the only currently available drug that actively clears mature *P. falciparum* gametocytes and prevents malaria transmission to mosquitoes (1). The wide-scale use of primaquine is hampered by its hemolytic effect in people with glucose-6-phosphate dehydrogenase (G6PD) deficiency. The mutation deficiency alters G6PD enzyme function (2), exposing red blood cells to oxidative stress and resultant hemolysis in the presence of a stressor, such as primaquine (3, 4). Primaquine-induced hemolysis is dose related (1, 5, 6). While testing for G6PD deficiency is widely recommended prior to the radical treatment of *Plasmodium vivax* with 14 days of primaquine, *P. falciparum* transmission may be considerably reduced by a single, low dose of primaquine (1, 7) and may avoid the necessity to screen for G6PD deficiency. We determined G6PD enzyme function and the presence of the most common African G6PD mutation (G6PD A–; 202A/376G) in a cohort of Ugandan children treated with low-dose primaquine for clearing *P. falciparum* gametocytes. This was a randomized, double-blinded placebo controlled trial with four parallel arms. Ugandan children 1 to 10 years old with uncomplicated *P. falciparum* malaria, hemoglobin concentration (Hb) of ≥ 8 g/dl, and normal

G6PD enzyme function based on a fluorescent spot test (FST; R&D Diagnostics, Agia Paraskevi, Greece) were enrolled and randomized to treatment with artemether lumefantrine (AL) alone or with a single dose of primaquine at 0.1, 0.4, or 0.75 mg/kg of body weight on the last day of AL treatment (7, 8). Genotyping of G6PD 202A and G6PD 376G was performed (9, 10). Hb was measured on days 0, 1, 2, 3, 7, 10, 14, 21, and 28 after enrollment by HemoCue 201+ (Angelholm, Sweden) and expressed as absolute and relative change compared to baseline values. These values were normally distributed, presented using mean values and standard deviations, and analyzed using linear regression models. Because the age distribution of the red blood cell population influences the severity of drug-induced hemolysis (11), we adjusted all

Received 27 March 2014 Returned for modification 30 April 2014

Accepted 3 June 2014

Published ahead of print 9 June 2014

Address correspondence to Teun Bousema, teun.bousema@shtm.ac.uk.

Supplemental material for this article may be found at <http://dx.doi.org/10.1128/AAC.02889-14>.

Copyright © 2014, Eziefula et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 3.0 Unported license](http://creativecommons.org/licenses/by/3.0/). doi:10.1128/AAC.02889-14

TABLE 1 Baseline characteristics

Characteristic	Value by G6PD 202 A– genotype			P value for difference from wild type	P value for difference from wild type
	Wild type	Heterozygous	Homozygous/hemizygous		
No. of participants (% study population)	373 (80.9)	61 (13.2)	27 (5.9)		
% female (no. of females/total no. of participants)	46.7 (174/373)	100.0 (61/61)	3.7 (1/27)	<0.001	<0.001
Mean (SD) age in yrs	5.0 (2.6)	4.8 (2.3)	4.9 (2.4)	0.61	0.86
Mean (SD) baseline Hb concn in g/dl	11.2 (1.5)	11.4 (1.4)	10.9 (1.4)	0.20	0.38
% 376G genotype (no. of participants with genotype/total no.)					
Heterozygous	18.6 (69/371)	78.7 (48/61)	0.0 (0/27)		
Homozygous	12.9 (48/371)	21.3 (13/61)	100.0 (27/27)	<0.001	<0.001

TABLE 2 G6PD 202 A⁻ genotype and hemoglobin levels^a

Characteristic	Value by treatment arm			
	0.75 mg/kg primaquine	0.4 mg/kg primaquine	0.1 mg/kg primaquine	Placebo
No. of study participants				
G6PD normal	98	90	93	92
G6PD heterozygous	14	13	16	18
G6PD hemizygous/homozygous	4	10	6	7
Mean absolute change (SD) in Hb on day 7				
G6PD normal, in g/dl	-0.41 (0.95)	-0.25 (1.22)	-0.30 (1.07)	-0.11 (1.33)
G6PD heterozygous, in g/dl	-1.08 (1.14)	-0.99 (1.48)	-0.07 (0.98)	-0.49 (1.40)
<i>P</i> value	0.048	0.054	0.35	0.28
G6PD hemizygous/homozygous, in g/liter	-1.10 (1.34)	-0.48 (0.76)	-0.07 (1.21)	-1.02 (0.81)
<i>P</i> value	0.21	0.043	0.91	0.22
% relative change (SD) in Hb on day 7, in g/dl				
G6PD normal	-3.25 (8.60)	-1.28 (11.24)	-2.16 (9.71)	-0.23 (11.34)
G6PD heterozygous	-9.38 (10.4)	-7.79 (12.57)	-0.01 (8.56)	-3.26 (12.26)
<i>P</i> value	0.044	0.073	0.34	0.33
G6PD hemizygous/homozygous	-7.97 (12.40)	-4.29 (7.70)	-0.05 (11.45)	-8.59 (7.28)
<i>P</i> value	0.36	0.028	0.93	0.16

^a On day 7 after initiation of treatment with artemether-lumefantrine (AL) plus placebo or AL plus different doses of primaquine. All primaquine or placebo treatment was administered together with six doses of AL; primaquine/placebo was given on day 2 of treatment, together with dose 5 of AL. *P* values are compared to G6PD-normal individuals, adjusted for baseline Hb concentration.

comparisons for baseline Hb concentration. All trial participants ($n = 468$) were G6PD normal by FST. DNA was available for 461 individuals of whom 27 (5.9%) were homozygous/hemizygous, 61 were heterozygous (13.2%), and 373 (80.9%) were normal for the G6PD variant A⁻ (wild type [WT]). All individuals with the 202A mutation also had the 376G mutation, and individuals were classified based on the 202A mutation (Table 1). G6PD 202 A⁻ heterozygous individuals experienced a mean reduction in Hb concentration on day 7 after treatment of 1.08 g/dl (standard deviation [SD], 1.14; $P = 0.048$) in the 0.75-mg/kg treatment arm and 0.99 g/dl (SD, 1.48; $P = 0.054$) in the 0.4-mg/kg treatment arm (Table 2). Homozygous/hemizygous individuals in the 0.75-mg/kg and 0.4-mg/kg arms also experienced a reduction in absolute Hb concentration on day 7, although this was statistically significant in the 0.4-mg/kg arm only ($P = 0.043$). When changes in Hb concentration on day 7 were expressed as a proportion of baseline Hb concentration, the same trend was observed with statistically significant decreases in the 0.75-mg/kg arm for heterozygous individuals and in the 0.4-mg/kg arm for homozygous/hemizygous individuals. No statistically significant changes in absolute or relative Hb concentrations were observed for heterozygous or homozygous/hemizygous individuals in the 0.1-mg/kg arm or placebo arm (Table 2). We found no explanation for the numerically large, but statistically nonsignificant, reduction in Hb concentration in homozygous/hemizygous individuals on day 7 after receiving AL without primaquine. A previous study found no hemolysis after AL in homozygous/hemizygous individuals (12), and we conclude our observation may be a spurious finding and related to our small sample size. We observed no statistically significant associations between G6PD genotype and absolute or relative Hb concentrations in any treatment arm on days 3 and 10 after initiation of treatment (see the supplemental material). Sixty-nine individuals experienced a reduction of >2 g/dl in the first 2 weeks of follow-up: 13.7% (51/373) of the WT individuals, 26.2% (16/61; $P = 0.031$) of the heterozygous individuals, and 7.4% (2/27; $P = 0.48$) of the G6PD 202 A⁻ homozygous/hemizy-

gous individuals ($P = 0.020$). For all individuals, Hb concentrations normalized during follow-up. The current findings provide important data on the hemolytic effect of single-, low-dose primaquine. Our results show that the predominant test for G6PD deficiency screening, the FST (13), failed to identify a substantial proportion of individuals who were genotypically G6PD deficient, particularly female heterozygotes, who experienced significant reductions in hemoglobin following higher doses of primaquine. The observation that some G6PD-deficient individuals were FST normal is unsurprising since the test may be insufficiently sensitive to detect mild G6PD deficiency (13), but there are few supportive published data. We observed statistically significant decreases in Hb following single-dose primaquine in these G6PD-deficient individuals. A hemolytic effect of a single dose of 0.75 mg/kg primaquine base has been reported before (6); our study shows that a reduction in Hb concentrations is also evident after a single dose of 0.4 mg/kg but not 0.1 mg/kg. Moreover, reductions in Hb were transient, with no participant experiencing clinical symptoms suggestive of anemia and none requiring related clinical care. Although these findings are notable, a major limitation of the study is that individuals who were determined G6PD deficient based on the FST were excluded from the study ($n = 32$), thereby plausibly removing those most severely deficient and thereby those with the highest risk of primaquine-induced hemolysis. There is therefore a need for confirmatory trials to formally assess primaquine safety in G6PD-deficient individuals, in particular with the World Health Organization recommended dose of 0.25 mg/kg. Such studies will have to take into account interindividual differences in primaquine metabolism that determine primaquine efficacy in *P. vivax* (14) and potentially also safety.

ACKNOWLEDGMENTS

This study was funded primarily by a Wellcome Trust Bloomsbury Clinical Fellowship to A.C.E. (090558), supplemented by funds from the Bill & Melinda Gates Foundation to C.D. and T.B. (OPP1034789).

We thank the parents and guardians and study participants for their

patience and commitment and all members of the study team (notably Asiphas Owaraganise, Grace Gabagaya, Salome Opus, Samuel Okiror, Hamuza Isabirye, Josephine Zawedde, Abubaker Kawuba, Christobel Achen).

REFERENCES

- White NJ. 2013. Primaquine to prevent transmission of falciparum malaria. *Lancet Infect. Dis.* 13:175–181. [http://dx.doi.org/10.1016/S1473-3099\(12\)70198-6](http://dx.doi.org/10.1016/S1473-3099(12)70198-6).
- Alving AS, Carson PE, Flanagan CL, Ickes CE. 1956. Enzymatic deficiency in primaquine-sensitive erythrocytes. *Science* 124:484–485. <http://dx.doi.org/10.1126/science.124.3220.484>.
- Beutler E, Yeh M, Fairbanks VF. 1962. The normal human female as a mosaic of X-chromosome activity: studies using the gene for C-6-PD-deficiency as a marker. *Proc. Natl. Acad. Sci. U. S. A.* 48:9–16. <http://dx.doi.org/10.1073/pnas.48.1.9>.
- Beutler E. 1959. The hemolytic effect of primaquine and related compounds: a review. *Blood* 14:103–139.
- Alving AS, Johnson CF, Tarlov AR, Brewer GJ, Kellermeyer RW, Carson PE. 1960. Mitigation of the haemolytic effect of primaquine and enhancement of its action against exoerythrocytic forms of the Chesson strain of *Plasmodium vivax* by intermittent regimens of drug administration: a preliminary report. *Bull. World Health Organ.* 22:621–631.
- Shekalaghe SA, ter Braak R, Daou M, Kavishe R, van den Bijllaardt W, van den Bosch S, Koenderink JB, Luty AJ, Whitty CJ, Drakeley C, Sauerwein RW, Bousema T. 2010. In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A⁻) individuals. *Antimicrob. Agents Chemother.* 54:1762–1768. <http://dx.doi.org/10.1128/AAC.01135-09>.
- Eziefula AC, Bousema T, Yeung S, Kanya M, Owaraganise A, Gabagaya G, Bradley J, Grignard L, Lanke KH, Wanzira H, Mpimbaza A, Nsoby S, White NJ, Webb EL, Staedke SG, Drakeley C. 2014. Single dose primaquine for clearance of *Plasmodium falciparum* gametocytes in children with uncomplicated malaria in Uganda: a randomised, controlled, double-blind, dose-ranging trial. *Lancet Infect. Dis.* 14:130–139. [http://dx.doi.org/10.1016/S1473-3099\(13\)70268-8](http://dx.doi.org/10.1016/S1473-3099(13)70268-8).
- Eziefula AC, Staedke SG, Yeung S, Webb E, Kanya M, White NJ, Bousema T, Drakeley C. 2013. Study protocol for a randomised controlled double-blinded trial of the dose-dependent efficacy and safety of primaquine for clearance of gametocytes in children with uncomplicated falciparum malaria in Uganda. *BMJ Open* 3(3):pii=e002759. <http://dx.doi.org/10.1136/bmjopen-2013-002759>.
- Fanello CI, Karema C, Avellino P, Bancone G, Uwimana A, Lee SJ, d'Alessandro U, Modiano D. 2008. High risk of severe anaemia after chlorproguanil-dapsone+artesunate antimalarial treatment in patients with G6PD (A⁻) deficiency. *PLoS One* 3:e4031. <http://dx.doi.org/10.1371/journal.pone.0004031>.
- Hirono A, Beutler E. 1988. Molecular cloning and nucleotide sequence of cDNA for human glucose-6-phosphate dehydrogenase variant A(-). *Proc. Natl. Acad. Sci. U. S. A.* 85:3951–3954. <http://dx.doi.org/10.1073/pnas.85.11.3951>.
- Alving AS, Johnson CF, Tarlov AR, Brewer GJ, Kellermeyer RW, Carson PE. 1960. Mitigation of the haemolytic effect of primaquine and enhancement of its action against exoerythrocytic forms of the Chesson strain of *Plasmodium vivax* by intermittent regimens of drug administration: a preliminary report. *Bull. World Health Organ.* 22:621–631.
- Premji Z, Umeh RE, Owusu-Agyei S, Esamai F, Ezedinachi EU, Oguche S, Borrmann S, Sowunmi A, Duparc S, Kirby PL, Pamba A, Kellam L, Guiguemé R, Greenwood B, Ward SA, Winstanley PA. 2009. Chlorproguanil-dapsone-artesunate versus artemether-lumefantrine: a randomized, double-blind phase III trial in African children and adolescents with uncomplicated *Plasmodium falciparum* malaria. *PLoS One* 4:e6682. <http://dx.doi.org/10.1371/journal.pone.0006682>.
- Domingo GJ, Satyagraha AW, Anvikar A, Baird K, Bancone G, Bansil P, Carter N, Cheng Q, Culpepper J, Eziefula C, Fukuda M, Green J, Hwang J, Lacerda M, McGray S, Menard D, Nosten F, Nuchprayoon I, Oo NN, Bualombai P, Pumpradit W, Qian K, Recht J, Roca A, Satimai W, Sovannaroth S, Vestergaard LS, Von Seidlein L. 2013. G6PD testing in support of treatment and elimination of malaria: recommendations for evaluation of G6PD tests. *Malar. J.* 12:391. <http://dx.doi.org/10.1186/1475-2875-12-391>.
- Bennett JW, Pybus BS, Yadava A, Tosh D, Sousa JC, McCarthy WF, Deye G, Melendez V, Ockenhouse CF. 2013. Primaquine failure and cytochrome P-450 2D6 in *Plasmodium vivax* malaria. *N. Engl. J. Med.* 369:1381–1382. <http://dx.doi.org/10.1056/NEJMc1301936>.